MultiplexDX Publishes Third Landmark Study on Pancreatic Neuroendocrine Tumors
This year, MultiplexDX has reached another critical scientific milestone. Following two publications in the prestigious journal Nature Communications, we are proud to announce our third publication, this time in the international peer-reviewed journal BMC Cancer.
The study presents our latest research, which has strong potential for the development of innovative diagnostic tools for patients with pancreatic neuroendocrine tumors (PanNETs).
Through deep sequencing, our team identified specific miRNA–mRNA pairs and interactions that distinguish rare PanNET tumors from healthy tissue. These findings also reveal disruptions in key biological processes within PanNET cells. Importantly, the results provide a foundation for the discovery of more reliable biomarkers, which could significantly enhance diagnostic accuracy, disease prognosis, and the development of targeted therapies for patients with PanNET.
We are deeply grateful to our scientific team at MultiplexDX – especially Evan Paul and Natália Matyašovská – and to our long-time collaborator, Associate Professor Neil Renwick from Queen’s University, Canada.
This achievement reflects our continued commitment to translating cutting-edge science into practical innovations for patients worldwide.
Read more here: Deep sequencing reveals distinct microRNA-mRNA signatures that differentiate pancreatic neuroendocrine tumor from non-diseased pancreas tissue.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
